Literature DB >> 16424219

Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes.

Keira Reville1, John K Crean, Sharon Vivers, Ian Dransfield, Catherine Godson.   

Abstract

Lipoxins (LXs) are endogenously produced anti-inflammatory agents that modulate leukocyte trafficking and stimulate nonphlogistic macrophage phagocytosis of apoptotic neutrophils, thereby promoting the resolution of inflammation. Previous data suggest a role for altered protein phosphorylation and cytoskeletal rearrangement in LX-stimulated phagocytosis but the exact mechanisms remain unclear. In this study we examine the effects of LXA4 on the protein phosphorylation pattern of THP-1 cells differentiated into a macrophage-like phenotype. THP-1 cells stimulated with LXA4 (1 nM) exhibit dephosphorylation of a 220-kDa protein. Using mass spectrometry, this protein was identified as MYH9, a nonmuscle myosin H chain II isoform A, which is involved in cytoskeleton rearrangement. THP-1 cells treated with LXA4 adopt a polarized morphology with activated Cdc42 localized toward the leading edge and MYH9 localized at the cell posterior. Polarized distribution of Cdc42 is associated with Akt/PKB-mediated Cdc42 activation. Interestingly, the annexin-derived peptide Ac2-26, a recently described agonist for the LXA4 receptor, also stimulates macrophage phagocytosis, MYH9 dephosphorylation, and MYH9 redistribution. In addition, we demonstrate that LXA4 stimulates the phosphorylation of key polarity organization molecules: Akt, protein kinase Czeta, and glycogen synthase kinase-3beta. Inhibition of LXA4-induced Akt and protein kinase Czeta activity with specific inhibitors prevented LXA4-stimulated phagocytosis of both apoptotic polymorphonuclear neutrophils and lymphocytes, highlighting a potential use for LXA4 in the treatment of autoimmune diseases. Furthermore, phosphorylation and subsequent inactivation of glycogen synthase kinase-3beta resulted in an increase in phagocytosis similar to that of LXA4. These data highlight an integrated mechanism whereby LXA4 regulates phagocytosis through facilitative actin cytoskeleton rearrangement and cell polarization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424219     DOI: 10.4049/jimmunol.176.3.1878

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Resolvin D1 promotes the targeting and clearance of necroptotic cells.

Authors:  Brennan D Gerlach; Michael Marinello; Justin Heinz; Nicholas Rymut; Brian E Sansbury; Colin O Riley; Sudeshna Sadhu; Zeinab Hosseini; Yoko Kojima; Dale D Tang; Nicholas J Leeper; Matthew Spite; Margarida Barroso; Katey J Rayner; Gabrielle Fredman
Journal:  Cell Death Differ       Date:  2019-06-20       Impact factor: 15.828

Review 2.  Endogenous lipid mediators in the resolution of airway inflammation.

Authors:  O Haworth; B D Levy
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

3.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes.

Authors:  Jan M Schwab; Nan Chiang; Makoto Arita; Charles N Serhan
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

4.  Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes.

Authors:  Vitaliy Starosta; Konrad Pazdrak; Istvan Boldogh; Tetyana Svider; Alexander Kurosky
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

5.  Phagocytic clearance of apoptotic cells: role in lung disease.

Authors:  Jeong H Yun; Peter M Henson; Rubin M Tuder
Journal:  Expert Rev Respir Med       Date:  2008-12       Impact factor: 3.772

Review 6.  Novel anti-inflammatory--pro-resolving mediators and their receptors.

Authors:  Charles N Serhan; Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.

Authors:  Paola Maderna; David C Cottell; Tiina Toivonen; Neil Dufton; Jesmond Dalli; Mauro Perretti; Catherine Godson
Journal:  FASEB J       Date:  2010-06-22       Impact factor: 5.191

8.  Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.

Authors:  C P Lin; I Adrianto; C J Lessard; J A Kelly; K M Kaufman; J M Guthridge; B I Freedman; J-M Anaya; M E Alarcón-Riquelme; B A Pons-Estel; J Martin; S Glenn; A Adler; S-C Bae; S-Y Park; S-Y Bang; Y-W Song; S A Boackle; E E Brown; J C Edberg; G S Alarcón; M A Petri; L A Criswell; R Ramsey-Goldman; J D Reveille; L M Vila; G S Gilkeson; D L Kamen; J Ziegler; C O Jacob; A Rasmussen; J A James; R P Kimberly; J T Merrill; T B Niewold; R H Scofield; A M Stevens; B P Tsao; T J Vyse; C D Langefeld; K L Moser; J B Harley; P M Gaffney; C G Montgomery
Journal:  Genes Immun       Date:  2011-12-22       Impact factor: 2.676

Review 9.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 10.  Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology.

Authors:  Brian E Sansbury; Matthew Spite
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.